Flagship Pioneering and Samsung Announce Collaboration to Advance Groundbreaking Technologies in Translational Science and Medicine
CAMBRIDGE, Mass. and SEOUL, South Korea, Jan. 8, 2024 /PRNewswire/ — Flagship Pioneering, the bioplatform innovation company, and Samsung today announced a collaboration aimed at fostering cutting-edge biopharmaceutical innovation poised to transform the world of healthcare through groundbreaking advancements in translational science and medicine.
Related news for (MRNA)
- merck and moderna initiate phase 3 trial evaluating adjuvant v940 (mrna-4157) in combination with keytruda® (pembrolizumab) after neoadjuvant keytruda and chemotherapy in patients with certain types of non-small cell lung cancer (nsclc)
- carisma and moderna expand collaboration to develop two in vivo car-m therapies for autoimmune diseases
- Moderna Chief Executive Officer Stéphane Bancel Elected to National Academy of Engineering
- Moderna to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 22, 2024
- Moderna Named to Fortune’s List of World’s Most Admired Companies